Back to search results

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) for NMIBC

This study is testing a treatment called Intravesical Recombinant Mycobacterium (rMBCG) for people with non-muscle invasive bladder cancer (NMIBC). This treatment is given directly into the bladder using a catheter. The study is looking at how safe rMBCG is, by tracking any side effects over about 7 months. You might be able to join if you are 18 or older, have NMIBC that hasn't been treated with a similar drug called BCG before, and have a specific type of NMIBC (Carcinoma in situ or certain papillary tumors). The study plans to enroll about 40 participants and is currently open.

Study design
This is a Phase 1/2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll about 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will assess safety over approximately 7 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06800963

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Recruiting
PHASE1Ages 18–85InterventionalTreatment
ImmunityBio, Inc.
~40 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:Intravesical Recombinant Mycobacterium (rMBCG)

At a glance

Recruiting sites
5 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary endpoint is to assess safety as measured by the incidence and severity of adverse events.
Measured over Approximately 7 months

Conditions

NMIBC

Explore related trials

Non-Muscle Invasive Bladder Carcinoma

NCT06800963

Where you'd take part

This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Arizona Clinical Trials

    Chandler, Arizonastudy coordinator listed

    Not yet recruiting

  • Conrad Pearson Clinic

    Germantown, Tennesseestudy coordinator listed

    Not yet recruiting

  • Emory University

    Atlanta, Georgiastudy coordinator listed

    Recruiting

  • Golden State Urology

    Sacramento, Californiastudy coordinator listed

    Recruiting

  • Michigan Institute of Urology & Solaris Health

    Troy, Michiganstudy coordinator listed

    Recruiting

  • MidLantic Urology

    Cynwyd, Pennsylvaniastudy coordinator listed

    Recruiting

  • Potamac Urology Center

    Alexandria, Virginiastudy coordinator listed

    Not yet recruiting

  • SUNY Upstate Medical University

    Syracuse, New Yorkstudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Jayson Garmizo
[email protected]
310-912-2230
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • The primary endpoint is to assess safety as measured by the incidence and severity of adverse events.Approximately 7 months

    Safety assessments will include demographics/medical history, vital signs, hematology, chemistry, urinalysis, and pregnancy.